New therapy, new challenges: The effects of long-term continuous flow left ventricular assist device on inflammation. (15th July 2016)

• Record Type: Journal Article
• Authors: Grosman-Rimon, Liza; Billia, Filio; Fuks, Avi; Jacobs, Ira; A. McDonald, Michael; Cherney, David Z.; Rao, Vivek
• Is Part Of: International journal of cardiology. Volume 215(2016)
• Page Start: 424
• Page End: 430
• Publication Date: 2016-07-15
• Subjects: Continuous flow left ventricular assist devices (CF-LVADs) -- Heart failure (HF) inflammatory biomarkers; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2016.04.133
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Surgically implanted continuous flow left ventricular assist devices (CF-LVADs) are currently used in patients with end-stage heart failure (HF). However, CF-LVAD therapy introduces a new set of complications and adverse events in these patients. Major adverse events with the CF-LVAD include right heart failure, vascular dysfunction, stroke, hepatic failure, and multi-organ failure, complications that may have inflammation as a common etiology. Our aim was to review the current evidence showing a relationship between these adverse events and elevated levels of inflammatory biomarkers in CF-LVAD recipients. Highlights: Inflammation is elevated in patients with CF-LVAD support. Inflammation may have detrimental effects on CF-LVAD recipients. Future studies should examine strategies to reduce inflammation.